MYO1C and central nervous system cancer: To evaluate the effect of MYO1C‐rich EVs mediated by RAB31 on glioma progression, U87MG cells and GSC2 were treated with EVs from control GhECs (siNC), RAB31 knockdown GhEC (siRAB31), or NhECs.